The latest update is out from Veritas In Silico Inc. ( (JP:130A) ).
Veritas In Silico Inc. announced its strategy to enhance shareholder value by expanding its platform business through acquiring new contracts and creating in-house drug pipelines. The company aims to transform into a specialty pharmaceutical company by balancing revenue from its platform with investments in pipeline creation, having already signed a contract with LCC ahead of schedule.
More about Veritas In Silico Inc.
Veritas In Silico Inc. operates in the pharmaceutical industry, focusing on mRNA-targeted small molecule drug discovery. The company utilizes its proprietary drug discovery platform ibVIS® to collaborate with pharmaceutical companies and aims to create nucleic acid drug pipelines, transitioning towards a hybrid business model.
YTD Price Performance: -10.32%
Average Trading Volume: 52,632
Technical Sentiment Consensus Rating: Strong Buy
For a thorough assessment of 130A stock, go to TipRanks’ Stock Analysis page.